AHL Investment Management Inc. Boosts Holdings in Johnson & Johnson (NYSE:JNJ)

Posted by on Mar 26th, 2023

AHL Investment Management Inc. grew its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 4.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,934 shares of the company’s stock after purchasing an additional 621 shares during the quarter. Johnson & Johnson comprises approximately 2.3% of AHL Investment Management Inc.’s investment portfolio, making the stock its 18th biggest holding. AHL Investment Management Inc.’s holdings in Johnson & Johnson were worth $2,461,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Glassy Mountain Advisors Inc. acquired a new position in Johnson & Johnson during the 4th quarter valued at about $35,000. TD Capital Management LLC acquired a new position in shares of Johnson & Johnson during the third quarter valued at about $48,000. Cowa LLC acquired a new stake in Johnson & Johnson in the 3rd quarter worth approximately $58,000. Legend Financial Advisors Inc. purchased a new stake in Johnson & Johnson during the 3rd quarter worth approximately $59,000. Finally, Piershale Financial Group Inc. acquired a new position in Johnson & Johnson during the 4th quarter valued at approximately $61,000. 67.94% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on JNJ shares. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, February 1st. Atlantic Securities raised their price objective on Johnson & Johnson from $160.00 to $168.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 25th. Citigroup upped their target price on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, December 12th. SVB Leerink reduced their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research report on Friday, January 20th. Finally, Guggenheim assumed coverage on shares of Johnson & Johnson in a research note on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price objective on the stock. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $174.73.

Insider Activity

In related news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the transaction, the insider now directly owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.35% of the company’s stock.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $152.65 on Friday. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $186.69. The stock’s 50-day moving average price is $159.76 and its 200-day moving average price is $167.55. The stock has a market capitalization of $397.54 billion, a PE ratio of 22.65, a price-to-earnings-growth ratio of 2.60 and a beta of 0.54.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, beating the consensus estimate of $2.22 by $0.13. The company had revenue of $23.71 billion for the quarter, compared to analyst estimates of $23.90 billion. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. Johnson & Johnson’s quarterly revenue was down 4.4% compared to the same quarter last year. During the same period last year, the company earned $2.13 earnings per share. As a group, equities analysts expect that Johnson & Johnson will post 10.5 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st were issued a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a yield of 2.96%. The ex-dividend date was Friday, February 17th. Johnson & Johnson’s payout ratio is 67.06%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.

Featured Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.